Antialbuminuric Effects of Valsartan and Lisinopril

This study has been terminated.
(unknown)
Sponsor:
Information provided by (Responsible Party):
Novartis
ClinicalTrials.gov Identifier:
NCT00171600
First received: September 12, 2005
Last updated: November 7, 2011
Last verified: November 2011

September 12, 2005
November 7, 2011
July 2005
January 2007   (final data collection date for primary outcome measure)
Change from baseline in urine albumin excretion rate from collected urine samples, after 16 and 20 weeks
Not Provided
Complete list of historical versions of study NCT00171600 on ClinicalTrials.gov Archive Site
  • Blood pressure less than 130/80 mmHg after 16 and 20 weeks of treatment
  • Change from baseline 48-hour ambulatory blood pressure, and blood pressure less than 130/80 mmHg after 16 and 20 weeks of treatment
  • Blood pressure less than 130/80 mmHg at night, measured by 48-hour ambulatory blood pressure monitoring, after 16 and 20 weeks of treatment
  • Change from baseline in size of left heart ventricle by electrocardiogram (ECG) after 20 weeks
  • Change from baseline in kidney function after 16 and 20 weeks
Not Provided
Not Provided
Not Provided
 
Antialbuminuric Effects of Valsartan and Lisinopril
Comparative, Open Multicenter Trial Assessing the Effect on Albumin Excretion Rate of 320mg Valsartan (With or Without HCTZ) vs 40mg Lisinopril (With or Without HCTZ) on Hypertensive Patients With Diabetic and Non-diabetic Nephropathy and Albuminuria

Title: Antialbuminuric effect of valsartan, lisinopril and valsartan versus lisinopril in non-diabetic and diabetic renal disease: a randomized (3:3:1), open label, parallel group, 20 weeks follow-up.

Objective: To evaluate the antialbuminuric effect of high doses of valsartan vs lisinopril vs combo treatment in non-diabetic and diabetic patients.

Hypothesis: Combo treatment reduces microalbuminuria and the albumin/creatinine ratio more than monotherapies..

Design: Multicentric, randomized, open label, parallel group, active controlled.

Dose / regimen: Valsartan 320 vs Lisinopril 40 vs Valsartan/lisinopril 160/20

Primary Endpoint: Antialbuminuric effect of valsartan 320 mg, lisinopril and valsartan versus lisinopril 40 mg in non-diabetic and diabetic renal disease following 5 months of follow-up. Description % of change in albuminuria from baseline at 20 weeks.

Secondary Endpoint : To investigate the effect of 5 months treatment with valsartan,lisinopril and valsartan versus lisinopril in GFR (Cl creatinine), also to investigate the effect of 5 months treatment with valsartan, lisinopril and valsartan plus lisinopril on blood pressure and the effect on left ventricular mass index using electrocardiogram and Cornell-Sokolow method.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Hypertension
  • Early Diabetic Nephropathy
Drug: VALSARTAN, VALSARTAN PLUS HCTZ, LISINOPRIL, LISINOPRIL PLUS HCTZ
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
54
January 2007
January 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female outpatients aged 40-75 years,
  • Chronic nephropathy, as defined by a serum creatinine concentration of > 1.3 mg/dL or calculated glomerular filtration rate of > 30 mL/min/1.73 m2.
  • Persistent albuminuria, as defined by urinary albumin excretion exceeding 20 mg/ 24 h but not > 1000 mg/ 24h. (for a minimum of three months).
  • Hypertensive patients not adequately controlled with or without treatment (controlled: <130/80 mmHg).
  • Written informed consent to participate in the study prior to any study procedures.

Exclusion Criteria:

  • Immediate need for renal replacement therapy.
  • Treatment resistant oedema or nephrotic syndrome.
  • Need for treatment with corticosteroids, non-steroidal antiinflammatory drugs, or immunosuppressive drugs.
  • Albuminuria greater than 1000mg /24h and or less than 20mg/24h.
  • Total cholesterol < 135mg/dl or not need for statins treatment.
  • Renovascular hypertension
  • Malignant hypertension
  • MI, cerebrovascular accident within last year, severe peripheral vascular disease, CHF, chronic hepatic disease.
  • Angiotensin converting enzyme inhibitors and angiotensin II receptors blockers within one month prior to randomization.
  • A serum creatinine concentration >265 umol/L
Both
40 Years to 75 Years
Not Provided
Contact information is only displayed when the study is recruiting subjects
Switzerland
 
NCT00171600
CVAL489AES15
Not Provided
Novartis
Novartis
Not Provided
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Novartis
November 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP